secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-RAD LABORATORIES, INC. (BIO)
CIK:        0000012208
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0000012208-25-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Rad Q2 revenue up 2% to $652M; completes Stilla acquisition
---------------------------------------------------------------

- Q2 2025 revenue $651.6M (+2.1% YoY); GAAP net income $317.8M vs loss $2,165.5M (prior year included Sartorius losses).
- Non-GAAP EPS $2.61 vs $3.11; non-GAAP operating income $88.6M vs $106.9M, reflecting margin compression.
- GAAP gross margin 53.0% vs 55.6%; non-GAAP gross margin 53.7% vs 56.4%, down on product mix and costs.
- Completed acquisition of Stilla Technologies, expanding digital PCR portfolio with QX Continuum and QX700 systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/0000012208-25-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/12208/000001220825000051/bio-20250731.htm
  HTML page:      https://secwatch.observer/filing/0000012208-25-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer